AIA
ARRY

Alera Investment Advisors’s Array Biopharma Inc ARRY Stock Holding History

Alera Investment Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-19
Closed – – 1399
2018
Q4 		$0 Buy
+19
New +$288 ﹤0.01% 1198

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alera Investment Advisors's ARRY Position: Q1 2019 in Review

Alera Investment Advisors sold out of Array Biopharma Inc (ARRY) in Q1 2019, closing a stake of 19 shares.

Alera Investment Advisors first reported a position in ARRY in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 268 funds tracked by Wall St. Rank hold ARRY as of Q1 2019.

  • Alera Investment Advisors reported no remaining Array Biopharma Inc position as of Q1 2019 after selling out during the quarter.
  • Alera Investment Advisors sold 19 Array Biopharma Inc shares in Q1 2019.
  • Alera Investment Advisors first reported a position in Array Biopharma Inc in Q4 2018 and held it in 1 quarter.
  • Alera Investment Advisors's Array Biopharma Inc position peaked at $0 in Q4 2018.
  • 268 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2019.

Based on Alera Investment Advisors's 13F filing for Q1 2019, filed 14 May 2019.